JP2019531763A5 - - Google Patents

Download PDF

Info

Publication number
JP2019531763A5
JP2019531763A5 JP2019533313A JP2019533313A JP2019531763A5 JP 2019531763 A5 JP2019531763 A5 JP 2019531763A5 JP 2019533313 A JP2019533313 A JP 2019533313A JP 2019533313 A JP2019533313 A JP 2019533313A JP 2019531763 A5 JP2019531763 A5 JP 2019531763A5
Authority
JP
Japan
Prior art keywords
item
sequence
site
anchor sequence
specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019533313A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019531763A (ja
JP7682604B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/050553 external-priority patent/WO2018049073A1/en
Publication of JP2019531763A publication Critical patent/JP2019531763A/ja
Publication of JP2019531763A5 publication Critical patent/JP2019531763A5/ja
Priority to JP2023113050A priority Critical patent/JP2023119040A/ja
Application granted granted Critical
Publication of JP7682604B2 publication Critical patent/JP7682604B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019533313A 2016-09-07 2017-09-07 遺伝子発現をモジュレートするための方法および組成物 Active JP7682604B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023113050A JP2023119040A (ja) 2016-09-07 2023-07-10 遺伝子発現をモジュレートするための方法および組成物

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201662384603P 2016-09-07 2016-09-07
US62/384,603 2016-09-07
US201662416501P 2016-11-02 2016-11-02
US62/416,501 2016-11-02
US201662439327P 2016-12-27 2016-12-27
US62/439,327 2016-12-27
US201762542703P 2017-08-08 2017-08-08
US62/542,703 2017-08-08
PCT/US2017/050553 WO2018049073A1 (en) 2016-09-07 2017-09-07 Methods and compositions for modulating gene expression

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023113050A Division JP2023119040A (ja) 2016-09-07 2023-07-10 遺伝子発現をモジュレートするための方法および組成物

Publications (3)

Publication Number Publication Date
JP2019531763A JP2019531763A (ja) 2019-11-07
JP2019531763A5 true JP2019531763A5 (enExample) 2020-10-22
JP7682604B2 JP7682604B2 (ja) 2025-05-26

Family

ID=61562240

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019533313A Active JP7682604B2 (ja) 2016-09-07 2017-09-07 遺伝子発現をモジュレートするための方法および組成物
JP2023113050A Pending JP2023119040A (ja) 2016-09-07 2023-07-10 遺伝子発現をモジュレートするための方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023113050A Pending JP2023119040A (ja) 2016-09-07 2023-07-10 遺伝子発現をモジュレートするための方法および組成物

Country Status (7)

Country Link
US (5) US20190255106A1 (enExample)
EP (1) EP3510152A4 (enExample)
JP (2) JP7682604B2 (enExample)
CN (1) CN109890962A (enExample)
AU (2) AU2017324550B2 (enExample)
CA (1) CA3035910A1 (enExample)
WO (4) WO2018049075A1 (enExample)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US11053481B2 (en) 2013-12-12 2021-07-06 President And Fellows Of Harvard College Fusions of Cas9 domains and nucleic acid-editing domains
US20180250424A1 (en) 2014-10-10 2018-09-06 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
EP3215617B1 (en) 2014-11-07 2024-05-08 Editas Medicine, Inc. Systems for improving crispr/cas-mediated genome-editing
EP3294896A1 (en) 2015-05-11 2018-03-21 Editas Medicine, Inc. Optimized crispr/cas9 systems and methods for gene editing in stem cells
JP7396783B2 (ja) 2015-06-09 2023-12-12 エディタス・メディシン、インコーポレイテッド 移植を改善するためのcrispr/cas関連方法および組成物
WO2017053879A1 (en) 2015-09-24 2017-03-30 Editas Medicine, Inc. Use of exonucleases to improve crispr/cas-mediated genome editing
US12043852B2 (en) 2015-10-23 2024-07-23 President And Fellows Of Harvard College Evolved Cas9 proteins for gene editing
WO2017165826A1 (en) 2016-03-25 2017-09-28 Editas Medicine, Inc. Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
US11236313B2 (en) 2016-04-13 2022-02-01 Editas Medicine, Inc. Cas9 fusion molecules, gene editing systems, and methods of use thereof
CA3029132A1 (en) 2016-07-06 2018-01-11 Crispr Therapeutics Ag Materials and methods for treatment of pain related disorders
CN109843914B (zh) 2016-07-06 2024-03-15 沃泰克斯药物股份有限公司 用于治疗疼痛相关病症的材料和方法
GB2568182A (en) 2016-08-03 2019-05-08 Harvard College Adenosine nucleobase editors and uses thereof
WO2018031683A1 (en) 2016-08-09 2018-02-15 President And Fellows Of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
CA3034369A1 (en) 2016-08-19 2018-02-22 Whitehead Institute For Biomedical Research Methods of editing dna methylation
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
EP3510152A4 (en) 2016-09-07 2020-04-29 Flagship Pioneering, Inc. METHODS AND COMPOSITIONS FOR MODULATING GENE EXPRESSION
GB2573062A (en) 2016-10-14 2019-10-23 Harvard College AAV delivery of nucleobase editors
WO2018111944A1 (en) 2016-12-12 2018-06-21 Whitehead Institute For Biomedical Research Regulation of transcription through ctcf loop anchors
WO2018119010A1 (en) 2016-12-19 2018-06-28 Editas Medicine, Inc. Assessing nuclease cleavage
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
US12110545B2 (en) 2017-01-06 2024-10-08 Editas Medicine, Inc. Methods of assessing nuclease cleavage
US11873496B2 (en) 2017-01-09 2024-01-16 Whitehead Institute For Biomedical Research Methods of altering gene expression by perturbing transcription factor multimers that structure regulatory loops
CN118370844A (zh) 2017-02-07 2024-07-23 加利福尼亚大学董事会 单倍体机能不全的基因疗法
WO2018165631A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Cancer vaccine
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
CN110914310A (zh) 2017-03-10 2020-03-24 哈佛大学的校长及成员们 胞嘧啶至鸟嘌呤碱基编辑器
US11268082B2 (en) 2017-03-23 2022-03-08 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable DNA binding proteins
EP3615672A1 (en) 2017-04-28 2020-03-04 Editas Medicine, Inc. Methods and systems for analyzing guide rna molecules
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
CN110997908A (zh) 2017-06-09 2020-04-10 爱迪塔斯医药公司 工程化的cas9核酸酶
WO2019014564A1 (en) 2017-07-14 2019-01-17 Editas Medicine, Inc. SYSTEMS AND METHODS OF TARGETED INTEGRATION AND GENOME EDITING AND DETECTION THEREOF WITH INTEGRATED PRIMING SITES
JP2020534795A (ja) 2017-07-28 2020-12-03 プレジデント アンド フェローズ オブ ハーバード カレッジ ファージによって支援される連続的進化(pace)を用いて塩基編集因子を進化させるための方法および組成物
WO2019139645A2 (en) 2017-08-30 2019-07-18 President And Fellows Of Harvard College High efficiency base editors comprising gam
CA3082251A1 (en) 2017-10-16 2019-04-25 The Broad Institute, Inc. Uses of adenosine base editors
JP7401432B2 (ja) 2017-12-01 2023-12-19 エンコーデッド セラピューティクス, インコーポレイテッド 操作されたdna結合タンパク質
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
US12480140B2 (en) 2018-05-06 2025-11-25 Emendobio Inc. Differential knockout of an allele of a heterozygous ELANE gene
US12157760B2 (en) 2018-05-23 2024-12-03 The Broad Institute, Inc. Base editors and uses thereof
CA3104856A1 (en) 2018-06-29 2020-01-02 Editas Medicine, Inc. Synthetic guide molecules, compositions and methods relating thereto
CA3109592A1 (en) * 2018-08-23 2020-02-27 Sangamo Therapeutics, Inc. Engineered target specific base editors
EA202092684A1 (ru) 2018-08-27 2021-03-11 Ридженерон Фармасьютикалз, Инк. Применение рамановской спектроскопии для последующей очистки
WO2020081598A1 (en) * 2018-10-15 2020-04-23 Flagship Pioneering Innovations V, Inc. Disrupting genomic complex assembly in fusion genes
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
US20220024999A1 (en) * 2018-11-29 2022-01-27 Flagship Pioneering Innovations V, Inc. Methods of modulating rna
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
WO2020176553A1 (en) * 2019-02-25 2020-09-03 Sense Therapeutics Inc. Intracellular mutation targeting therapy
CL2020000712A1 (es) * 2019-03-18 2020-11-20 Sound Agriculture Company Control epigenético programable de la expresión génica en plantas
AU2020240109A1 (en) 2019-03-19 2021-09-30 President And Fellows Of Harvard College Methods and compositions for editing nucleotide sequences
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
CA3141900C (en) * 2019-05-29 2023-06-06 Encoded Therapeutics, Inc. Compositions and methods for selective gene regulation
CN114729376A (zh) 2019-09-23 2022-07-08 欧米茄治疗公司 用于调节肝细胞核因子4α(HNF4α)基因表达的组合物和方法
WO2021061640A1 (en) * 2019-09-23 2021-04-01 Flagship Pioneering Innovations V, Inc. Compositions and methods for modulating genomic complex integrity index
CA3154759A1 (en) * 2019-09-23 2021-04-01 Flagship Pioneering Innovations V, Inc. Modulating genomic complexes
CA3147641A1 (en) 2019-09-23 2021-04-01 Omega Therapeutics, Inc. Compositions and methods for modulating apolipoprotein b (apob) gene expression
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
JP2022553855A (ja) * 2019-11-06 2022-12-26 エメンドバイオ・インコーポレイテッド 長さが21~30ヌクレオチドのガイド配列を使用したヘテロ接合elane遺伝子の対立遺伝子のさまざまなノックアウト
US12258599B2 (en) 2019-11-06 2025-03-25 Emendobio Inc. Method to inactivate a mutant allele of an ELANE gene
US12435334B2 (en) 2019-11-06 2025-10-07 Emendobio Inc. Differential knockout of an allele of a heterozygous ELANE gene-II
EP4061968A4 (en) * 2019-11-22 2023-12-27 National University of Singapore Method and system for identifying and validating shared candidate antigens and shared antigen-specific t lymphocyte pairs
CA3162809A1 (en) * 2020-01-17 2021-07-22 Nzumbe, Inc. Induction of dna strand breaks at chromatin targets
EP4112719A1 (en) * 2020-02-26 2023-01-04 Aisin Corporation Gene knock-in method, method for producing gene knock-in cell, gene knock-in cell, canceration risk evaluation method, cancer cell production method, and kit for use in same
IL296024A (en) 2020-03-04 2022-10-01 Flagship Pioneering Innovations Vi Llc Methods and compositions for modulating a genome
JP2023517326A (ja) 2020-03-11 2023-04-25 オメガ セラピューティクス, インコーポレイテッド フォークヘッドボックスp3(foxp3)遺伝子発現をモジュレートするための組成物および方法
US20230201269A1 (en) * 2020-04-24 2023-06-29 Spinalcyte, Llc Treatment of frontotemporal dementia using fibroblasts and products thereof
BR112022022603A2 (pt) 2020-05-08 2023-01-17 Broad Inst Inc Métodos e composições para edição simultânea de ambas as fitas de sequência alvo de nucleotídeos de fita dupla
EP4222259A4 (en) * 2020-09-29 2025-07-23 Flagship Pioneering Innovations V Inc COMPOSITIONS AND METHODS FOR INHIBITING THE EXPRESSION OF MULTIPLE GENES
CN112301020B (zh) * 2020-10-19 2024-04-12 复旦大学附属肿瘤医院 Iii类脱氧核酶突变体及其制备方法与应用
CN114621959B (zh) * 2020-12-08 2023-05-26 中国科学院海洋研究所 一种编码牙鲆igf2可溶性蛋白的基因及蛋白重组表达方法与应用
IL303923A (en) * 2020-12-22 2023-08-01 Chroma Medicine Inc Compositions and methods for epigenetic editing
WO2022197857A1 (en) * 2021-03-16 2022-09-22 The General Hospital Corporation Compositions and methods for the treatment of conditions associated with nucleotide repeat expansion
EP4367242A2 (en) 2021-07-07 2024-05-15 Omega Therapeutics, Inc. Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression
US20230116385A1 (en) * 2021-08-30 2023-04-13 Sachi Bioworks Inc. Composition of a therapeutic oligomer
MX2024002927A (es) 2021-09-08 2024-05-29 Flagship Pioneering Innovations Vi Llc Metodos y composiciones para modular un genoma.
WO2023225349A2 (en) * 2022-05-20 2023-11-23 Helex Inc. Tissue specific methods and compositions for gene editing
KR20250068590A (ko) * 2022-06-22 2025-05-16 플래그쉽 파이어니어링 이노베이션스 브이, 인크. Myc 발현을 조절하기 위한 제형
CN119421711A (zh) * 2022-06-22 2025-02-11 旗舰先锋创新V股份有限公司 包含myc调节的组合疗法
AU2024270764A1 (en) 2023-05-15 2025-12-04 Nchroma Bio, Inc. Compositions and methods for epigenetic regulation of hbv gene expression
WO2024238723A1 (en) 2023-05-16 2024-11-21 Omega Therapeutics, Inc. Methods and compositions for modulating pcsk9 expression
WO2024238726A1 (en) 2023-05-16 2024-11-21 Omega Therapeutics, Inc. Methods and compositions for modulating methylation of a target gene
WO2024243438A2 (en) 2023-05-23 2024-11-28 Omega Therapeutics, Inc. Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression
WO2025019742A1 (en) 2023-07-19 2025-01-23 Omega Therapeutics, Inc. Methods and compositions for modulating ctnnb1 expression
WO2025085423A1 (en) * 2023-10-19 2025-04-24 The Broad Institute, Inc. Method of multi-locus crispri targeting with a single truncated guide
CN118773200B (zh) * 2024-07-18 2025-06-10 华中科技大学同济医学院附属同济医院 一种ttc21b基因突变位点及其应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20084393B (en) 2003-04-24 2008-06-10 Incyte Corp Aza spiro alkane derivatives as inhibitors of metalloproteases
WO2009146033A2 (en) 2008-03-31 2009-12-03 Sma Foundation Compositions and methods for modulating smn activity
AU2009336191B2 (en) 2008-12-18 2017-08-24 Novo Nordisk A/S Extended dicer substrate agents and methods for the specific inhibition of gene expression
US8828718B2 (en) 2009-04-03 2014-09-09 Centre National De La Recherche Scientifique Gene transfer vectors comprising genetic insulator elements and methods to identify genetic insulator elements
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2012138973A2 (en) * 2011-04-06 2012-10-11 The University Of Chicago COMPOSITION AND METHODS RELATED TO MODIFICATION OF 5-METHYLCYTOSINE (5mC)
KR102271292B1 (ko) * 2013-03-15 2021-07-02 더 제너럴 하스피탈 코포레이션 Rna-안내 게놈 편집의 특이성을 증가시키기 위한 rna-안내 foki 뉴클레아제(rfn)의 용도
US9234213B2 (en) * 2013-03-15 2016-01-12 System Biosciences, Llc Compositions and methods directed to CRISPR/Cas genomic engineering systems
US20160186208A1 (en) 2013-04-16 2016-06-30 Whitehead Institute For Biomedical Research Methods of Mutating, Modifying or Modulating Nucleic Acid in a Cell or Nonhuman Mammal
US10167466B2 (en) 2013-09-04 2019-01-01 Csir Site-specific nuclease single-cell assay targeting gene regulatory elements to silence gene expression
US9737604B2 (en) * 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
US9925277B2 (en) 2013-09-13 2018-03-27 Modernatx, Inc. Polynucleotide compositions containing amino acids
US20150376612A1 (en) * 2014-06-10 2015-12-31 The General Hospital Corporation CCCTC-Binding Factor (CTCF) RNA Interactome
US10286086B2 (en) 2014-06-19 2019-05-14 Modernatx, Inc. Alternative nucleic acid molecules and uses thereof
US9816074B2 (en) * 2014-07-25 2017-11-14 Sangamo Therapeutics, Inc. Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells
AU2015298571B2 (en) * 2014-07-30 2020-09-03 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
GB201418965D0 (enExample) 2014-10-24 2014-12-10 Ospedale San Raffaele And Fond Telethon
US20190100769A1 (en) 2014-10-31 2019-04-04 Massachusetts Institute Of Technology Massively parallel combinatorial genetics for crispr
EP3215617B1 (en) * 2014-11-07 2024-05-08 Editas Medicine, Inc. Systems for improving crispr/cas-mediated genome-editing
WO2016081798A1 (en) * 2014-11-20 2016-05-26 Children's Medical Center Corporation Methods relating to the detection of recurrent and non-specific double strand breaks in the genome
US11279974B2 (en) 2014-12-01 2022-03-22 The Broad Institute, Inc. Method for in situ determination of nucleic acid proximity
CA2968939A1 (en) 2014-12-24 2016-06-30 The Johns Hopkins University Systems and methods for genome modification and regulation
CN107429263A (zh) * 2015-01-15 2017-12-01 斯坦福大学托管董事会 调控基因组编辑的方法
US10023922B2 (en) 2015-03-23 2018-07-17 Whitehead Institute For Biomedical Research Reporter of genomic methylation and uses thereof
WO2016164356A1 (en) 2015-04-06 2016-10-13 The Board Of Trustees Of The Leland Stanford Junior University Chemically modified guide rnas for crispr/cas-mediated gene regulation
EP3087974A1 (en) * 2015-04-29 2016-11-02 Rodos BioTarget GmbH Targeted nanocarriers for targeted drug delivery of gene therapeutics
US20170014449A1 (en) * 2015-07-13 2017-01-19 Elwha LLC, a limited liability company of the State of Delaware Site-specific epigenetic editing
US20190005191A1 (en) 2015-07-14 2019-01-03 Whitehead Institute For Biomedical Research Chromosome neighborhood structures and methods relating thereto
AU2016308339A1 (en) * 2015-08-18 2018-04-12 Baylor College Of Medicine Methods and compositions for altering function and structure of chromatin loops and/or domains
EP3344766B8 (en) 2015-09-01 2021-03-17 Dana-Farber Cancer Institute, Inc. Systems and methods for selection of grna targeting strands for cas9 localization
CA2998287A1 (en) * 2015-09-24 2017-04-20 Crispr Therapeutics Ag Novel family of rna-programmable endonucleases and their uses in genome editing and other applications
US20170130247A1 (en) 2015-09-30 2017-05-11 Whitehead Institute For Biomedical Research Compositions and methods for altering gene expression
US11339442B2 (en) 2015-12-14 2022-05-24 The General Hospital Corporation Methods of detecting insulator dysfunction and oncogene activation for screening, diagnosis and treatment of patients in need thereof
JP2019508037A (ja) * 2016-02-16 2019-03-28 イェール ユニバーシティーYale Universit 標的化遺伝子編集を増強するための組成物およびその使用方法
GB201608000D0 (en) 2016-05-06 2016-06-22 Oxford Biodynamics Ltd Chromosome detection
CA3034369A1 (en) * 2016-08-19 2018-02-22 Whitehead Institute For Biomedical Research Methods of editing dna methylation
EP3510152A4 (en) 2016-09-07 2020-04-29 Flagship Pioneering, Inc. METHODS AND COMPOSITIONS FOR MODULATING GENE EXPRESSION
WO2018111944A1 (en) 2016-12-12 2018-06-21 Whitehead Institute For Biomedical Research Regulation of transcription through ctcf loop anchors
US11873496B2 (en) 2017-01-09 2024-01-16 Whitehead Institute For Biomedical Research Methods of altering gene expression by perturbing transcription factor multimers that structure regulatory loops
WO2018204764A1 (en) 2017-05-05 2018-11-08 Camp4 Therapeutics Corporation Identification and targeted modulation of gene signaling networks
EP3668993A4 (en) 2017-08-14 2021-05-12 Camp4 Therapeutics Corporation HEPATIC DISEASE TREATMENT METHODS
US20200255828A1 (en) 2017-10-04 2020-08-13 The Broad Institute, Inc. Methods and compositions for altering function and structure of chromatin loops and/or domains
EP3587516B1 (en) 2018-06-27 2024-05-22 Ricoh Company, Ltd. Ink, method of manufacturing acrylic resin particle, printing method, ink accommodating unit, and inkjet printing device

Similar Documents

Publication Publication Date Title
JP2019531763A5 (enExample)
TWI880645B (zh) 抑制lpa之基因表現之組合物及方法
US20170283830A1 (en) Compositions for enhancing targeted gene editing and methods of use thereof
US9828601B2 (en) Compositions for inhibiting checkpoint gene expression and uses thereof
JP2016513976A5 (enExample)
TW201920227A (zh) 用於抑制脂蛋白元C-III (APOC3)表現之RNAi試劑及組合物
US20210322577A1 (en) Methods and systems for modifying dna
CA3035910A1 (en) Methods and compositions for modulating gene expression
CA3014795A1 (en) Compositions and methods for treatment of cystic fibrosis
WO2018187493A1 (en) Compositions and methods for in utero delivery
US20180312839A1 (en) Methods and compositions for increasing smn expression
EP3573618B1 (en) Compositions and methods for hemoglobin production
JP2010515707A5 (enExample)
CN104769112A (zh) 用于在细胞中表达蛋白质的方法和产品
ES2291536T3 (es) Control de la expresion de gen usando un complejo de un oligonucleotido y un peptido regulatorio.
WO2021061815A1 (en) COMPOSITIONS AND METHODS FOR MODULATING HEPATOCYTE NUCLEAR FACTOR 4-ALPHA (HNF4α) GENE EXPRESSION
JP2006141402A5 (enExample)
JP2022512739A (ja) 操作された長鎖散在反復エレメント(line)トランスポゾンおよびそれらの使用方法
WO2021183720A1 (en) Compositions and methods for modulating forkhead box p3 (foxp3) gene expression
CA3097914A1 (en) Methods of gene therapy
Summerton Intracellular inactivation of specific nucleotide sequences: a general approach to the treatment of viral diseases and virally-mediated cancers
US20240279687A1 (en) Peptide nucleic acids for spatiotemporal control of crispr-cas binding
JP2020521491A5 (enExample)
JP2024530169A (ja) 方法
US20220243211A1 (en) Peptide nucleic acid compositions with modified hoogsteen binding segments and methods of use thereof